RebrAIn is pleased to announce the early completion of enrollment for the second phase of the PARKEO2 clinical trial, a pioneering study aimed at improving surgical treatments for Parkinson’s disease. Sponsored by the Bordeaux University Hospital (CHU de Bordeaux) and funded by the French government, the trial has successfully recruited 128 patients across 11 leading clinical sites.
The PARKEO2 trial represents a major milestone in advancing deep brain stimulation (DBS) treatments. Led by Professor Emmanuel Cuny, the randomized, double-blind study is the first of its kind to compare two different DBS surgical methods, with the goal of improving outcomes for Parkinson’s patients.
Collaboration Across Leading Medical Centers
The success of the PARKEO2 trial is a testament to the collaboration between some of France’s top medical institutions. Assistance Publique-Hôpitaux de Marseille (APHM), under the leadership of Professor Jean Régis, President of the World Society for Stereotactic and Functional Neurosurgery (WSSFN), played a crucial role as the leading recruitment center. Key contributions also came from Professor Denys Fontaine at Nice University Hospital and Dr. Emile Simon from the Hospices Civils de Lyon.
Leveraging AI for Enhanced Precision
At the core of the PARKEO2 trial is RebrAIn’s innovative use of artificial intelligence (AI) to enhance precision in neurosurgical planning. RebrAIn’s AI-powered software optimizes targeting for both DBS and lesioning techniques, enabling more personalized and precise treatments for patients. Recently approved by the FDA for a second indication, RebrAIn’s technology is transforming how neurosurgeons approach complex procedures.
“We are thrilled to have reached this milestone ahead of schedule,” said Professor Emmanuel Cuny, Principal Investigator of the PARKEO2 trial. “This achievement is a reflection of the dedication of our research teams and the commitment of our participants. We look forward to sharing the results of this groundbreaking study, which we believe will offer new hope for Parkinson’s patients worldwide.”
Looking Ahead
The PARKEO2 trial continues to progress, with data analysis and outcome assessment to follow. As RebrAIn’s cutting-edge AI solutions gain momentum, the company remains focused on driving innovation in Parkinson’s treatment and enhancing the lives of those affected by neurological disorders.
For more details on the PARKEO2 trial, please visit ClinicalTrials.gov (ID NCT04884412)
